GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Inventories, Other

Imugene (ASX:IMU) Inventories, Other : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Imugene Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Imugene's other inventories for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Imugene Inventories, Other Historical Data

The historical data trend for Imugene's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Inventories, Other Chart

Imugene Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imugene Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Imugene Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Imugene Business Description

Traded in Other Exchanges
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines